Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 10/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.60 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.60 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20073857 | 0.94 | FTO (0.67) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL19769261 | 0.93 | FTO (0.48) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL4572038 | 0.88 | FTO (0.72) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL18326523 | 0.86 | FTO (0.79) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL21527330 | 0.86 | FTO (0.66) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL12929974 | 0.85 | MAPT (0.57) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL19769291 | 0.84 | FTO (0.47) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL12863674 | 0.84 | FTO (0.85) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL19224760 | 0.84 | FTO (0.58) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL15496804 | 0.84 | FTO (0.86) | FTOMAPTHPGDMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | AUBURN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20180222916-A1 | FUNCTIONALIZED NANOLUC INHIBITORS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180104354-A1 | CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2018-04-19 | — | — | US | disclosed |
| US-20150238631-A1 | CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104354-A1 | CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF | ICOS, HAVCR2, CD2 | FTO 3696/4885MAPT 2599/4885HPGD 4238/4885 |
| US-20150238631-A1 | CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF | ICOS, HAVCR2, CD2 | FTO 3696/4885MAPT 2599/4885HPGD 4238/4885 |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | VIP, PTMS, IAPP | FTO 4813/4885MAPT 4013/4885HPGD 1136/4885 |
| US-20180222916-A1 | FUNCTIONALIZED NANOLUC INHIBITORS | RNGTT, LUC7L2, GUSB | FTO 2395/4885MAPT 4104/4885HPGD 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.